NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis

Breast Cancer Research

Table 1 Associations between clinicopathological characteristics and NEDD4 expression

Parameter	Status	Total	NEDD4 positive	NEDD4 negative	χ²	P
Age at diagnosis (years)	≤ 35	50	36	14	1.632	0.201
Age at diagnosis (years)	> 35	395	248	147
Menopausal status	Premenopausal	240	158	82	0.914	0.339
Menopausal status	Postmenopausal	205	126	79
Tumor size (cm)	T1a/b	67	36	31	8.973	0.030
	T1c	127	73	54
	T2	220	153	67
	T3	31	22	9
Tumor grade	1	39	25	14	2.358	0.308
	2	204	120	84
	3	144	89	55
	Unknown	58	50	8
Nodal status	Positive	182	132	50	10.111	0.001
Nodal status	Negative	263	152	111
ER status	Positive	296	199	97	4.451	0.035
ER status	Negative	149	85	64
PR status	Positive	306	206	100	5.197	0.023
PR status	Negative	139	78	61
Her2 status	Positive	120	68	52	3.641	0.056
Her2 status	Negative	325	216	109
Ki-67 status	≤ 20%	133	82	51	0.385	0.535
Ki-67 status	> 20%	312	202	110
P53 status	Positive	299	190	109	0.291	0.590
	Negative	104	63	41
	Unknown	42	31	11
Molecular subtype	Luminal A	64	44	20	6.161	0.104
	Luminal B	267	177	90
	Her2+	73	43	30
	TNBC	41	20	21

Tumor size: 0.1 cm < T1a/b < 1 cm; 1 cm ≤ T1c < 2 cm; 2 cm ≤ T2 < 5 cm; 5 cm ≤ T3
Abbreviations: NEDD4 neural precursor cell-expressed developmentally downregulated gene 4, ER estrogen receptor, Her2 human epidermal growth factor receptor 2, PR progesterone receptor, TNBC triple negative breast cancer

ISSN: 1465-542X